In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Nucana (NCNA), with a price target of $10.00. The company’s shares closed last Friday at $7.00.
According to TipRanks.com, Burns is a 5-star analyst with an average return of 53.6% and a 78.0% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nucana with a $17.33 average price target, implying a 132.6% upside from current levels. In a report issued on January 13, Oppenheimer also assigned a Buy rating to the stock with a $20.00 price target.
See today’s analyst top recommended stocks >>
Based on Nucana’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $8.39 million. In comparison, last year the company had a GAAP net loss of $3.88 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology is consists of acelarin, NUC-3373, and NUC-7738. The company was founded by Hugh S. Griffith and Christopher B. Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.
Read More on NCNA:
